Theratechnologies Inc. Extends Patent Protection for Tesamorelin in the Treatment of HIV-Associated Lipodystrophy

MONTREAL, CANADA--(Marketwire - January 08, 2008) - Theratechnologies (TSX: TH) today announced that the United States Patent and Trademark Office has issued Patent Number 7,316,997 entitled "GH Secretagogues and Uses Thereof" to Theratechnologies. This patent covers methods of treatment of HIV-associated lipodystrophy using Theratechnologies' lead investigational new drug, tesamorelin (TH9507). The granting of this patent extends the patent protection of tesamorelin in HIV-associated lipodystrophy for eight additional years.